Vijaya Diagnostic Centre Limited has informed the Exchange regarding Audited Financial Results for the quarter and year ended March 31, 2025.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre reported healthy FY25 results with consolidated revenue from operations growing ~24% to Rs 68,139 lakhs (from Rs 54,781 lakhs in FY24) and profit for the year up ~20% to Rs 14,379 lakhs. Standalone revenue rose to Rs 62,714 lakhs with net profit of Rs 13,501 lakhs. Statutory auditor B S R and Co issued an unmodified (clean) opinion on both standalone and consolidated results. The board recommended a final dividend of Rs 2 per share (200% on face value of Re 1), subject to shareholder approval. Additionally, Mr S. Ramachandra Reddy was appointed as Interim CFO and Mr Lanka Sai Srinivas as CTO; 1.91 lakh ESOPs were granted at Rs 815 per option, and the scheme to merge subsidiary Medinova Diagnostic Services awaits final NCLT approval.
Strong topline growth, clean audit, and a 200% dividend signal solid financial health and reward shareholders positively, while the CFO change and pending Medinova merger could draw near-term attention from investors.